Cadrenal Therapeutics (CVKD) Competitors $12.92 -0.08 (-0.62%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$12.98 +0.06 (+0.46%) As of 07/11/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. FBRX, CLLS, CLYM, CABA, MCRB, TCRX, VNRX, SRZN, EPIX, and PLRXShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Forte Biosciences (FBRX), Cellectis (CLLS), Climb Bio (CLYM), Cabaletta Bio (CABA), Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), VolitionRx (VNRX), Surrozen (SRZN), ESSA Pharma (EPIX), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Its Competitors Forte Biosciences Cellectis Climb Bio Cabaletta Bio Seres Therapeutics TScan Therapeutics VolitionRx Surrozen ESSA Pharma Pliant Therapeutics Forte Biosciences (NASDAQ:FBRX) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Does the media refer more to FBRX or CVKD? In the previous week, Forte Biosciences had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 3 mentions for Forte Biosciences and 1 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 1.87 beat Forte Biosciences' score of 1.29 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Forte Biosciences Positive Cadrenal Therapeutics Very Positive Do analysts prefer FBRX or CVKD? Forte Biosciences currently has a consensus target price of $61.00, suggesting a potential upside of 478.20%. Cadrenal Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 147.68%. Given Forte Biosciences' higher possible upside, equities analysts plainly believe Forte Biosciences is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is FBRX or CVKD more profitable? Forte Biosciences' return on equity of -149.15% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -149.15% -114.25% Cadrenal Therapeutics N/A -244.94%-181.94% Do institutionals and insiders hold more shares of FBRX or CVKD? 77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation & earnings, FBRX or CVKD? Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$35.48M-$16.29-0.65Cadrenal TherapeuticsN/AN/A-$10.65M-$9.26-1.40 Which has more risk & volatility, FBRX or CVKD? Forte Biosciences has a beta of 2.97, suggesting that its share price is 197% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. SummaryForte Biosciences beats Cadrenal Therapeutics on 8 of the 12 factors compared between the two stocks. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.57M$2.99B$5.60B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-1.4020.5827.9620.25Price / SalesN/A292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book3.107.638.045.49Net Income-$10.65M-$55.05M$3.18B$250.27M7 Day Performance5.13%8.39%3.63%4.75%1 Month Performance-13.81%5.35%4.04%7.64%1 Year PerformanceN/A1.95%29.55%16.34% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics2.9547 of 5 stars$12.92-0.6%$32.00+147.7%N/A$25.57MN/A-1.404Positive NewsFBRXForte Biosciences3.5262 of 5 stars$12.93+5.6%$61.00+371.8%+40,918.7%$80.65MN/A-0.795Positive NewsOptions VolumeGap DownCLLSCellectis3.3631 of 5 stars$1.53+5.2%$4.00+162.3%-20.9%$80.60M$49.22M-1.77290CLYMClimb Bio3.508 of 5 stars$1.24+5.1%$9.00+625.8%N/A$79.74MN/A-0.529News CoveragePositive NewsCABACabaletta Bio2.5851 of 5 stars$1.52-3.2%$14.43+849.2%-78.8%$79.67MN/A-0.6050News CoveragePositive NewsGap UpMCRBSeres Therapeutics3.3243 of 5 stars$11.11+22.1%$73.67+563.1%-35.7%$79.46M$126.32M-2.42330Positive NewsGap DownHigh Trading VolumeTCRXTScan Therapeutics3.6093 of 5 stars$1.45+3.6%$7.80+437.9%-73.5%$79.23M$2.82M-1.33100News CoveragePositive NewsAnalyst UpgradeVNRXVolitionRx2.1165 of 5 stars$0.76-9.3%$3.50+360.5%+3.5%$78.30M$1.31M-2.1180News CoverageAnalyst ForecastSRZNSurrozen2.7693 of 5 stars$8.94-0.9%$38.50+330.6%-12.4%$77.24M$10.65M-0.3680Positive NewsGap DownHigh Trading VolumeEPIXESSA Pharma1.9304 of 5 stars$1.70-1.7%$2.00+17.6%-67.4%$76.79MN/A-2.7050Positive NewsPLRXPliant Therapeutics4.4941 of 5 stars$1.16-7.2%$13.31+1,047.6%-88.7%$76.73M$1.58M-0.3290News CoverageHigh Trading Volume Related Companies and Tools Related Companies FBRX Competitors CLLS Competitors CLYM Competitors CABA Competitors MCRB Competitors TCRX Competitors VNRX Competitors SRZN Competitors EPIX Competitors PLRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.